CAS 720691-69-0

GSK-239512

Description:

GSK-239512, with the CAS number 720691-69-0, is a chemical compound that has been studied primarily for its potential therapeutic applications. It belongs to a class of compounds known as selective serotonin reuptake inhibitors (SSRIs), which are commonly used in the treatment of various mood disorders, including depression and anxiety. The compound exhibits a specific mechanism of action by selectively inhibiting the reuptake of serotonin in the brain, thereby increasing its availability in the synaptic cleft and enhancing serotonergic neurotransmission. GSK-239512 has been characterized by its moderate lipophilicity, which influences its bioavailability and pharmacokinetic properties. Additionally, it has shown a favorable safety profile in preclinical studies, although its efficacy and safety in humans would require thorough clinical evaluation. As with many investigational drugs, ongoing research is essential to fully understand its pharmacological effects, potential side effects, and therapeutic applications.

1-(6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy)pyridin-3-yl)pyrrolidin-2-one

CAS: 720691-69-0

Formula: C₂₃H₂₇N₃O₂

Purity: 95%

Molecular weight: 377.4794

Ref: IN-DA00IC7V

GSK-239512

CAS: 720691-69-0

GSK-239512

Purity: ≥98%

Molecular weight: 377.48g/mol

Ref: 54-BUP16238

1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE

CAS: 720691-69-0

Formula: C₂₃H₂₇N₃O₂

Purity: 95.0%

Color and Shape: Solid

Molecular weight: 377.488

Ref: 10-F387863

GSK-239512

CAS: 720691-69-0

GSK-239512 is a potent and selective histamine H3 receptor antagonist, which is a compound developed by GSK, derived from extensive pharmacological research. This organic compound acts by selectively inhibiting the H3 receptor subtype, which modulates the release of neurotransmitters in the central nervous system, including histamine, acetylcholine, and norepinephrine.

The pharmacological action of GSK-239512 involves attenuating the inhibitory action of histamine on neurotransmitter release, thereby increasing wakefulness and enhancing cognitive processes. This mechanism makes it a compelling candidate in the context of researching treatments for cognitive disorders such as Alzheimer's disease and attention-deficit hyperactivity disorder (ADHD).

In preclinical studies, GSK-239512 has demonstrated encouraging results in improving cognition and memory. Its application extends to experimental models where modulating central histaminergic pathways is explored for therapeutic benefits. Current investigations aim to determine its efficacy and safety profiles in human clinical trials, where it continues to be pivotal in understanding histaminergic neuromodulation's role in cognitive enhancement and neuroprotection.

Formula: C₂₃H₂₇N₃O₂

Purity: Min. 95%

Molecular weight: 377.48 g/mol

Ref: 3D-VDB69169

GSK-239512

CAS: 720691-69-0

GSK-239512 is an antagonist of H3 receptor and can be used in studies about the treatment of cognitive dysfunction in neurodegenerative disorders.

Formula: C₂₃H₂₇N₃O₂

Purity: 99.62% - 99.74%

Color and Shape: Solid

Molecular weight: 377.48

Ref: TM-T27462